Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant

Pituitary

Volumn 13, Issue 1, 2010, Pages 89-93

  Roemmler, J ^a   Bidlingmaier, M ^a   Schopohl, J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acromegaly; Estradiol; Growth hormone receptor antagonist pegvisomant; IGF I

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; GROWTH HORMONE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; CASE REPORT; DISEASE ACTIVITY; ESTRADIOL BLOOD LEVEL; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; INSULIN BLOOD LEVEL; OLIGOMENORRHEA; PRIORITY JOURNAL; PROTEIN BINDING; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ESTRADIOL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; RECEPTORS, SOMATOTROPIN;

EID: 77949270852     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-008-0131-5     Document Type: Article

References (23)

1. A Juul SA Pedersen S Sorensen, et al. 1994 Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset Eur J Endocrinol 131 41 49 10.1530/eje.0.1310041 1:STN:280:DyaK2czhtlartQ%3D%3D 7518728
2. KY Ho WS Evans RM Blizzard, et al. 1987 Effects of sex and age on the 24-h profile of growth hormone secretion in man: importance of endogenous estradiol concentrations J Clin Endocrinol Metab 64 51 58 10.1210/jcem-64-1-51 1:CAS:528:DyaL2sXnvFSmsg%3D%3D 3782436
3. G van den Berg JD Veldhuis M Frolich, et al. 1996 An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women J Clin Endocrinol Metab 81 2460 2467 10.1210/jc.81.7.2460 10.1210/jc.81.7.2460 8675561 (Pubitemid 26240261)
4. HK Gleeson SM Shalet 2005 GH responsiveness varies during the menstrual cycle Eur J Endocrinol 153 775 779 10.1530/eje.1.02037 10.1530/eje.1.02037 1:CAS:528:DC%2BD28XjtVWnuw%3D%3D 16322382 (Pubitemid 43020227)
5. P Ovesen N Vahl S Fisker, et al. 1998 Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women J Clin Endocrinol Metab 83 1662 1667 10.1210/jc.83.5.1662 10.1210/jc.83.5.1662 1:CAS:528:DyaK1cXjtF2gsrY%3D 9589674 (Pubitemid 28501040)
6. P Vestergaard AP Hermann H Orskov, et al. 1999 Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study J Clin Endocrinol Metab 84 2286 2290 10.1210/jc.84.7.2286 10.1210/jc.84.7.2286 1:CAS:528:DyaK1MXks1agt7g%3D 10404791
7. AJ Weissberger KK Ho L Lazarus 1991 Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-h growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women J Clin Endocrinol Metab 72 374 381 10.1210/jcem-72-2-374 1:CAS:528:DyaK3MXlt1Ontrc%3D 1991807
8. KE Friend ML Hartman SS Pezzoli, et al. 1996 Both oral and transdermal estrogen increase growth hormone release in postmenopausal women-a clinical research center study J Clin Endocrinol Metab 81 2250 2256 10.1210/jc.81.6.2250 10.1210/jc.81.6.2250 1:CAS:528:DyaK28XjsFyksbw%3D 8964860 (Pubitemid 26176712)
9. AF Bristow RP Gooding RE Das 1990 The international reference reagent for insulin-like growth factor-I J Endocrinol. 125 191 197 10.1677/joe.0.1250191 1:CAS:528:DyaK3cXitFWjtLo%3D 2373974
10. MO Thorner CJ Strasburger Z Wu, et al. 1999 Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH J Clin Endocrinol Metab 84 2098 2103 10.1210/jc.84.6.2098 10.1210/jc.84.6.2098 1:CAS:528:DyaK1MXjs1OhsLs%3D 10372717
11. AF Muller JA Janssen LJ Hofland, et al. 2001 Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance J Clin Endocrinol Metab 86 590 593 10.1210/jc.86.2.590 10.1210/jc.86.2.590 1:CAS:528:DC%2BD3MXht1KnsLY%3D 11158013 (Pubitemid 32207463)
12. S Stadler Z Wu RA Dressendorfer, et al. 2001 Monoclonal anti-acid-labile subunit oligopeptide antibodies and their use in a two-site immunoassay for ALS measurement in humans J Immunol Methods. 252 73 82 10.1016/S0022-1759(01)00335-0 10.1016/S0022-1759(01)00335-0 1:CAS:528:DC%2BD3MXjtFGjt7w%3D 11334967 (Pubitemid 32382091)
13. KM Morrison M Bidlingmaier S Stadler, et al. 2007 Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly Eur J Endocrinol. 156 331 339 10.1530/EJE-06-0592 10.1530/EJE-06-0592 1:CAS:528:DC%2BD2sXjvFCmt7w%3D 17322493 (Pubitemid 46554501)
14. LM Carlsson AM Rowland RG Clark, et al. 1991 Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood J Clin Endocrinol Metab 73 1216 1223 10.1210/jcem-73-6-1216 1:CAS:528:DyaK38XhsVOgtLY%3D 1955503
15. CD Pflaum RA Dressendorfer CJ Strasburger 1993 A non isotopic solid phase immunoassay for the determination of growth hormone binding protein (hGHBP) Exp Clin Endocrinol Diabetes 101 suppl. 1 44
16. CA Lissett SM Shalet 2003 The impact of dose and route of estrogen administration on the somatotropic axis in normal women J Clin Endocrinol Metab 88 4668 4672 10.1210/jc.2003-022036 10.1210/jc.2003-022036 1:CAS:528: DC%2BD3sXoslemtrg%3D 14557438 (Pubitemid 37357509)
17. RC Baxter 1994 Insulin-like growth factor binding proteins in the human circulation: a review Horm Res. 42 140 144 10.1159/000184186 1:CAS:528:DyaK2MXitlOqs74%3D 7532612
18. E Chin J Zhou J Dai, et al. 1994 Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex Endocrinology 134 2498 2504 10.1210/en.134.6.2498 10.1210/en.134.6.2498 1:CAS:528:DyaK2cXktVWqtrY%3D 7515002 (Pubitemid 24170863)
19. KC Leung G Johannsson GM Leong, et al. 2004 Estrogen regulation of growth hormone action Endocr Rev. 25 693 721 10.1210/er.2003-0035 10.1210/er.2003-0035 1:CAS:528:DC%2BD2cXhtVSjtrnN 15466938 (Pubitemid 39366048)
20. RT Scott Jr B Ross C Anderson, et al. 1991 Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol Obstet Gynecol 77 758 764 2014092
21. ME Wilson 1998 Effects of estradiol and exogenous insulin-like growth factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism J Clin Endocrinol Metab 83 4013 4021 10.1210/jc.83.11.4013 10.1210/jc.83.11.4013 1:CAS:528:DyaK1cXntlOitLg%3D 9814485
22. JJ Kelly IA Rajkovic AJ O'Sullivan, et al. 1993 Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in postmenopausal women Clin Endocrinol (Oxf) 39 561 567 10.1111/j.1365-2265.1993.tb02410.x 10.1111/j.1365-2265.1993.tb02410.x 1:CAS:528:DyaK2cXhsFCjt7s%3D
23. AJ van der Lely RK Hutson PJ Trainer, et al. 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist Lancet 358 1754 1759 10.1016/S0140-6736(01)06844-1 10.1016/S0140-6736(01)06844-1 11734231 (Pubitemid 33152999)